Skip to main content

Clinical Trials Using Enfortumab Vedotin

Review the clinical trials studying enfortumab vedotin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 29

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Status: Active
Location: 28 locations
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Status: Active
Location: 27 locations
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Status: Active
Location: 15 locations
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Status: Active
Location: 13 locations
Enfortumab Vedotin for the Treatment of Patients with Recurrent and/or Metastatic Adenoid Cystic Carcinoma
Status: Active
Location: 7 locations
Sacituzumab Govitecan, Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Location: 6 locations
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Status: Active
Location: 9 locations
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Patients with Localized Muscle-Invasive Bladder Cancer
Status: Active
Location: 5 locations
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Status: Active
Location: 4 locations
Enfortumab Vedotin for the Treatment of Patients with Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Status: Active
Location: 3 locations
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Location: 3 locations
Neoadjuvant Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with Upper Tract Urothelial Cancer, NEPTUNE Trial
Status: Active
Location: 2 locations
Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with High Grade Upper Tract Urothelial Cancer who are not Candidates for, or Refuse, Nephroureterectomy
Status: Active
Location: 2 locations
Enfortumab Vedotin and Pembrolizumab Induction with Pembrolizumab Maintenance for the Treatment of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma
Status: Active
Location: 2 locations
Enfortumab Vedotin plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Status: Active
Location: 3 locations
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Status: Active
Location: 3 locations
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Enfortumab Vedotin for the Treatment of Patients with Unresectable or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
De-escalated Pembrolizumab Monotherapy after Pembrolizumab Plus Enfortumab Vedotin for the Treatment of Unresectable, Locally Advanced, or Metastatic Urothelial Cancer in Patients with Circulating Tumor Deoxyribonucleic Acid Response, CT-READ Trial
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Pembrolizumab and Enfortumab Vedotin with Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Therapeutic Plasma Exchange with Enfortumab Vedotin and Pembrolizumab for the Treatment of Metastatic Refractory Bladder and Urinary Tract Cancers, RECIPE-B1 Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Stereotactic Radiotherapy and Enfortumab Vedotin for the Treatment of Patients with Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington